Semax + Selank
aka Semax/Selank
Mechanism
Pre-mixed blend of Semax (an ACTH(4-10) analog) and Selank (a heptapeptide tuftsin analog), both developed at the Russian Institute of Molecular Genetics. The individual compounds are registered as prescription drugs in Russia (intranasal); neither is FDA- or EMA-approved. The blend itself is NOT clinically validated — no controlled trial has tested Semax and Selank co-administered.
Identification
| Typical dose | Semax 200–600 mcg + Selank 250–500 mcg intranasally per session, typically 1–2x/day; often combined in equal-ratio nasal spray formulations |
|---|---|
| Half-life | Semax plasma ~2–5 min; Selank plasma ~2–10 min; CNS/functional effects of both extend several hours beyond clearance |
Vendors selling Semax + Selank
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Ion Peptide | — | $59.00 | — | 95 |
| Strate Labs | 10 mg | $64.95 | — | — |
Research
Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.
source →We studied the effects of peptide drugs (HLDF-6, PGP, RPGP, and PGLP) and peptide pharmaceutical products (Semax, Selank, and thyroliberin) on proliferation and survival of mouse embryonic stem cells and their derivatives. Differentiation of mouse embryonic stem cells into neuronal precursors was evaluated.
source →The present concept of relative instability of regulatory peptides (RPs) in organisms must be amended. The recently characterized family of glyprolines and some other prolyl-glycyl-proline (PGP)-containing oligopeptides show the stability quite comparable with those of major pharmacological preparations.
source →